Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504320 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Febuxostat XR Relative Bioavailability Study
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT02504320 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 78 participants.
The verdict
NCT02504320, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.
Interventions
- DRUG Febuxostat XR 80 mg Capsule F1
- DRUG Febuxostat XR 80 mg Capsule F2
- DRUG Febuxostat XR 80 mg Capsule F3
- DRUG Febuxostat XR 80 mg Capsule F4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02504320
The ClinicalTrials.gov registry entry for NCT02504320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Febuxostat XR 80 mg Capsule F1 is the first listed.
NCT02504320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02504320 about?
NCT02504320 is a clinical study titled "Phase 1, Febuxostat XR Relative Bioavailability Study". This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.
What is the current status of trial NCT02504320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2015-08. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02504320?
The interventions under investigation include: Febuxostat XR 80 mg Capsule F1 (DRUG), Febuxostat XR 80 mg Capsule F2 (DRUG), Febuxostat XR 80 mg Capsule F3 (DRUG), Febuxostat XR 80 mg Capsule F4 (DRUG).
Who is sponsoring clinical trial NCT02504320?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.